Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$15.00
Provider: Edison Investment Research
$10.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioLine Rx Ltd's BL-8040 Receives Orphan Drug Designation For Treatment Of AML


Monday, 9 Sep 2013 07:00am EDT 

BioLine Rx Ltd announced that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to BL-8040 as a therapeutic for the treatment of acute myeloid leukemia (AML). BL-8040 is a clinical-stage drug candidate for the treatment of acute myeloid leukemia, as well as other types of hematological cancers. 

Company Quote

70.1
-3.6 -4.88%
16 Apr 2014